Arterial ocular occlusion associated with systemic venous thrombophilia - 2 Case reports;Arterielle okuläre gefäßverschlüsse bei systemischer venöser thrombophilie - 2 Kasuistiken

Klinische Monatsblatter fur Augenheilkunde

Volumn 223, Issue 11, 2006, Pages 908-913

  Leifert, Dorothee ^a,c   Auw Hadrich C ^b   Leifert, J A ^b  

^a UNIVERSITY EYE CLINIC   (Switzerland)

^b UNIVERSITY OF FREIBURG   (Germany)

^c Univ Augenspital Basel   (Switzerland)

Author keywords

Arterial venous shunt; Paradoxical embolism; Thrombophilia; Vascular ocular occlusion

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN;

ADULT; ARTERY PERFUSION; ARTICLE; BRANCH RETINAL ARTERY OCCLUSION; CASE REPORT; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; HUMAN; HYPERHOMOCYSTEINEMIA; MALE; OPTIC NERVE DISEASE; RISK FACTOR; THROMBOPHILIA; VEIN THROMBOSIS;

EID: 33846309253     PISSN: 00232165     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-927095     Document Type: Article

References (69)

1. Almawi WY, Tamim H, Kreidy R et al. A case control study on the contribution of factor V-Leiden, prothrombin G20210A, and MTHFR C677T mutations to the genetic susceptibility of deep venous thrombosis. J Thromb Thrombolys 2005; 19: 189-196
2. Arsene S, Delahousse B, Regina S et al. Increased prevalence of factor V Leiden in patients with retinal vein occlusion and under 60 years of age. Thromb Haemost 2005; 94: 101-106
3. B-Vitamin T reatment Trialists' Collaboration. Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. Am Heart J 2006; 151 (2): 282-287
4. Ben-Ami R, Zeltser D, Leibowitz I et al. Retinal artery occlusion in a patient with factor V Leiden and prothrombin G20210A mutations. Blood Coagul Fibrinolysis 2002; 13 (1): 57-59
5. Bertina RM, Koeleman BPC, Koster T et al. Mutation in the blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 360: 64-67
6. Biller J, Johnson MR, Adams HP Jr et al. Further observations on cerebral or retinal ischemia in patients with right-left intracardiac shunts. Arch Neurol 1987; 44 (7): 740-743
7. Blom HJ. Genetic determinants of hyperhomocysteinaemia: the roles of cystathionine beta-synthase and 5,10-methylenetetrahydrofolate reductase. Eur J Pediatr 2000; 159 (Suppl 3): S208-212
8. Brown BA, Marx JL, Ward TP et al. Homocysteine: a risk factor for retinal venous occlusive disease. Ophthalmology 2002; 109 (2): 287-290
9. Cahill MT, Stinnett SS, Fekrat S. Meta-analysis of plasma homocysteine, serum folate, serum vitamin B(12), and thermolabile MTHFR genotype as risk factors for retinal vascular occlusive disease. Am J Ophthalmol 2003; 136 (6): 1136-1150
10. Cahill M, Karabatzaki M, Donoghue C et al. Thermolabile MTHFR genotype and retinal vascular occlusive disease. Br J Ophthalmol 2001; 85 (1): 88-90
11. Ciardella AP, Yanuzzi LA, Freund KB et al. Factor V Leiden, activated protein C resistance, and retinal vein occlusion. Retina 1998; 18 (4): 308-315
12. Cushman M. Inherited risk factors for venous thrombosis. Hematology (Am Soc Hematol Educ Program) 2005: 452-457
13. Cushman M, Rosendaal FR, Psaty BM et al. Factor V Leiden is not a risk factor for arterial vascular disease in the elderly: results from the cardiovascular health study. Thromb Haemost 1998; 79: 912-915
14. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognised mechanism characterised by a poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008
15. den Heijer M, Rosendaal FR, Blom HJ et al. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost 1998; 80: 874-877
16. Dorweiler B, Neufang A, Kasper-Koenig W et al. Arterial embolism to the upper extremity in a patient with factor V Leiden mutation (APC resistance). Angiology 2003; 54: 125-130
17. Dudman NP. An alternative view of homocysteine. Lancet 1999; 354 (9195): 2072-2074
18. Faude S, Faude F, Siegemund A et al. Activated protein C resistance in patients with central retinal vein occlusion in comparison to patients with a history of deep-vein thrombosis and a healthy control group. Ophthalmologe 1999; 96 (9): 549-599
19. Fegan CD. Central retinal vein occlusion and thrombophilia. Eye 2002; 16: 98-106
20. Foerch C, Kessler KR, Sitzer M. Brain infarctions caused by paradoxical embolism during long-distance flights. Dtsch Med Wochenschr 2003; 128: 196-198
21. Fowler B. Homocysteine: Overview of Biochemistry, Molecular Biology, and Role in Disease Processes. Semin Vasc Med 2005; 5 (2): 77-86
22. Frosst P, Blom HJ, Milos R et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-113
23. Gautier JC, Durr A, Koussa S et al. Paradoxal cerebral embolism: role of patent oval foramen. Bull Acad Natl Med 1990; 174 (7): 1031-1038
24. Gellekink H, den Heijer M, Heil SG et al. Genetic determinants of plasma total homocysteine. Semin Vasc Med 2005; 5 (2): 98-109
25. Gerling J, Janknecht P, Hansen LL et al. Diameter of the optic nerve in idiopathic optic neuritis and in anterior ischemic optic neuropathy. Int Ophthalmol 1997; 21 (3): 131-135
26. Glueck CJ, Wang P, Bell H et al. Nonarteritic anterior ischemic optic neuropathy: associations with homozygosity for the C677T methylenetetrahydrofolate reductase mutation. J Lab Clin Med 2004; 143 (3): 184-192
27. Gottlieb JL, Blice JP, Mestichelli B et al. Activated protein C resistance, factor V Leiden, and central retinal vein occlusion in young adults. Arch Ophthalmol 1998; 116: 577-579
28. Gomez F, Rodriguez A, Rivas J et al. Mesenteric arterial thrombosis due to activated protein C resistance (factor V Leiden). Surgery 2000; 128: 494-496
29. Graham SL, Goldberg I, Murray B et al. Activated protein C resistance - low incidence in glaucomatous optic disc haemorrhage and central retinal vein occlusion. Aust N Z Ophthalmol 1996; 24: 199-205
30. Greiner K, Hafner G, Prellwitz W et al. Hereditary disorders of the protein C system in central artery and branch arteriolar occlusions. Klin Monatsbl Augenheilkd 1999; 215 (1): 33-36
31. Greiner K, Peetz D, Winkgen A et al. Genetic thrombophilia in patients with retinal vascular occlusion. Int Ophthalmol 1999; 23: 155-160
32. Grossmann R, Schwender S, Geisen U et al. CBS 844ins68, MTHFR TT677 and EPCR 4031ins23 genotypes in patients with deep-vein thrombosis. Thromb Res 2002; 107 (1-2): 13-15
33. Hanson NQ, Aras O, Yang F et al. C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase gene: incidence and effect of combined genotypes on plasma fasting and post-methionine load homocysteine in vascular disease. ClinChem 2001; 47 (4): 661-666
34. Hodgkins PR, Perry DJ, Sawcer SJ et al. Factor V and antithrombin gene mutations in patients with idiopathic central retinal vein occlusion. Eye 1995; 9: 760-762
35. Hsu TS, Hsu LA, Chang CJ et al. Importance of hyperhomocysteinemia as a risk factor for venous thromboembolism in a Taiwanese population. A case-control study. Thromb Res 2001; 102 (5): 387-395
36. Huisman MV, Rosendaal F. Thrombophilia. Curr Opin Hematol 1999; 6 (5): 291-297
37. Janssen MC, den Heijer M, Cruysberg JR et al. Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombophilic factors. Thromb Haemost 2005; 93 (6): 1021-1026
38. Karttunen V, Hiltunen L, Rasi V et al. Factor V Leiden and prothrombin gene mutation may predispose to paradoxical embolism in subjects with patent foramen ovale. Blood Coagul Fibrinolysis 2003; 14 (3): 261-268
39. Kawasaki A, Purvin VA, Burgett RA. Hyperhomocysteinaemia in young patients with non-arteritic anterior ischaemic optic neuropathy. Br J Ophthalmol 1999; 83 (11): 1287-1290
40. Kim D, Saver JL. Patent foramen ovale and stroke: what we do and don't know. Rev Neurol Dis 2005; 2 (1): 1-7
41. Kluijtmans LAJ, Kastelein JJP, Lindemans J et al. Thermolabile methylenetetra-hydrofolate reductase in coronary artery disease. Circulation 1997; 96: 2573-2577
42. Kluijtmans LA, Whitehead AS. Methylenetetrahydrofolate reductase genotypes and predisposition to atherothrombotic disease; evidence that all three MTHFR C677T genotypes confer different levels of risk. Eur Heart J 2001; 22 (4): 294-299
43. Koster T, Rosendaal FRR, de Ronde H et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-1506
44. Larsson J, Sellman A, Bauer B. Activated protein C resistance in patients with central retinal vein occlusion. Br J Ophthalmol 1997; 81: 832-834
45. Linna, Ylikorkala A, Kontula K et al. Prevalence of factor V leiden in young adults with retinal vein occlusion. Thromb Haemost 1997; 77: 212-224
46. Longstreth WT Jr, Rosendaal FR, Siscovick DS et al. Risk of stroke in young women and two prothrombotic mutations: Factor V Leiden and prothrombin gene variant (G20210A). Stroke 1998; 29: 577-580
47. Marcucci R, Giusti B, Betti I et al. Genetic determinants of fasting and post-methionine hyperhomocysteinemia in patients with retinal vein occlusion. Thromb Res 2003; 110 (1): 7-12
48. Marcucci R, Bertini L, Giusti B et al. Thrombophilic risk factors in patients with central retinal vein occlusion. Thromb Haemost 2001; 86 (3): 772-776
49. van der Meer FJM, Koster T, Vandenbroucke JP et al. The Leiden Thrombophilia Study (LETS). Thromb Haemost 1997; 78: 631-635
50. Middendorf K, Gohring P, Huehns TY et al. Prevalence of resistance against activated protein C resulting from factor V Leiden is significantly increased in myocardial infarction: investigation of 507 patients with myocardial infarction. Am Heart J 2004; 147 (5): 897-904
51. Pianka P, Almog Y, Man O et al. Hyperhomocystinemia in patients with nonarteritic anterior ischemic optic neuropathy, central retinal artery occlusion, and central retinal vein occlusion. Ophthalmology 2000; 107 (8): 1588-1592
52. Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med 1998; 158: 2101-2106
53. Rees DC, Cox M, Clegg JB. World distribution of Factor V Leiden. Lancet 1995; 346: 1133-1134
54. Salomon O, Moisseiev J, Rosenberg N et al. Analysis of genetic polymorphisms related to thrombosis and other risk factors in patients with retinal vascular occlusion. Blood Coagul Fibrinolysis 1998; 9: 617-622
55. Salomon O, Huna-Baron R, Kurtz S et al. Analysis of prothrombotic and vascular risk factors in patients with nonarteritic anterior ischemic optic neuropathy. Ophthalmology 1999; 106 (4): 739-742
56. Schnyder G, Roffi M, Pin R et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001; 345: 1593-1600
57. De Stejano V, Chiusolo P, Paciaroni K et al. Epidemiology of Factor V Leiden: clinical implications. Semin Thromb Hemost 1998; 24: 367-379
58. Steuber C, Panzner B, Steuber T et al. Open foramen ovale in patients with arterial vascular occlusions of the retina and optic nerve. Curr Opin Ophthalmol 1997; 8 (3): 3-7
59. Tobis MJ, Azarbal B. Does patent foramen ovale promote cryptogenic stroke and migraine headache? Tex Heart Inst J 2005; 32 (3): 362-365
60. Di Tullio M, Sacco RL, Gopal A et al. Patent foramen ovale a sa risk factor for crytogenic stroke. Ann Intern Med 2004; 164 (9): 950-956
61. Vendu A, Cazorla MR, Granados MA et al. Basilar artery thrombosis in a child heterozygous for factor V Leiden mutation. Pediatric Neurology 2001; 24: 69-71
62. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002; 325: 1202
63. Wald DS, Bishop L, Wald NJ et al. Randomised trial of folic acid supplementation on serum homocysteine levels. Arch Intern Med 2001; 161: 695-700
64. Weger M, Renner W, Pinter O et al. Role of factor V Leiden and prothrombin 20210A in patients with retinal artery occlusion. Eye 2003; 17 (6): 731-734
65. Weger M, Renner W, Steinbrugger I et al. Role of thrombophilic gene polymorphisms in branch retinal vein occlusion. Ophthalmology 2005; 112 (11): 1910-1915
66. Weger M, Stanger O, Deutschmann H et al. Hyperhomocyst(e)inaemia, but not MTHFR C677T mutation, as a risk factor for non-arteritic ischaemic optic neuropathy. Br J Ophthalmol 2001; 85 (7): 803-806
67. Weger M, Stanger O, Deutschmann H et al. Hyperhomocyst(e)inemia and MTHFR C677T genotypes in patients with central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2002; 240 (4): 286-290
68. Williamson TH, Rumley A, Lowe GDO. Blood viscosity, coagulation and activated protein C resistance in central retinal vein occlusion: a population controlled study. Br J Ophthalmol 1996; 80: 203-208
69. Wu LA, Malouf JF, Dearani JA et al. Patent foramen ovale in cryptogenic stroke: current understanding and management options. Arch Intern Med 2004; 164 (9): 950-956